Syndax Pharmaceuticals, Inc.
SNDX
$11.05
-$0.28-2.47%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 23.29% | 84.72% | 42.72% | -- | -- |
| Gross Profit | -11.56% | -49.25% | -31.45% | -- | -- |
| SG&A Expenses | 65.46% | 80.14% | 94.86% | 92.48% | 123.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.55% | 81.13% | 56.44% | 72.80% | 85.34% |
| Operating Income | -23.70% | -58.95% | -49.39% | -72.80% | -85.34% |
| Income Before Tax | -29.94% | -64.48% | -52.56% | -76.04% | -84.91% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -29.94% | -64.48% | -52.56% | -76.04% | -84.91% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -29.94% | -64.48% | -52.56% | -76.04% | -84.91% |
| EBIT | -23.70% | -58.95% | -49.39% | -72.80% | -85.34% |
| EBITDA | -23.70% | -58.96% | -49.40% | -72.80% | -85.35% |
| EPS Basic | -9.85% | -34.49% | -24.58% | -43.44% | -61.13% |
| Normalized Basic EPS | -9.83% | -34.48% | -24.60% | -43.44% | -61.15% |
| EPS Diluted | -9.32% | -34.49% | -24.58% | -43.44% | -61.35% |
| Normalized Diluted EPS | -9.83% | -34.48% | -24.60% | -43.44% | -61.15% |
| Average Basic Shares Outstanding | 18.30% | 22.30% | 22.45% | 22.72% | 14.76% |
| Average Diluted Shares Outstanding | 18.30% | 22.30% | 22.45% | 22.72% | 14.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |